Group items matching

in title, tags, annotations or url

Resistance exercise did not increase muscle concentrations of Testosterone in men or women.  The individuals in this study were actively training.  These were not sedentary individuals.

three year follow up study of 1031 men >40.  The study found a reduction in mortality with Testosterone treatment (10.3%) versus a mortality rate of 20.7% in men not treated.  This is a second study that points to a reduction in mortality with normalization of Testosterone levels with Testosterone therapy.  Breaking out of the mode, that Testosterone is also therapeutic not just a biomarker in men.

low Testosterone is associated with increased mortality in men and Testosterone therapy in men with low T is associated with a reduction in mortality in men.

Study of 2361 Chinese men found that men with MetS had lower TT, bioavailable Testosterone, free Testosterone and SHBG than those men without MetS.  Additionally, Total Testosterone and SHBG were both inversely associated with the risk of MetS.  This inverse association stood for both after adjusting for the other.

Small study of 2 men with type II diabetes finds fasting glucose levels negatively correlate with total and free Testosterone levels, HgbA1c negatively correlated with SHBG only, total cholesterol and LDL negatively correlated with SHBG and total testosterone.  The prevalence of type II diabetes was higher with low free Testosterone than total Testosterone, but both were statistically significant.

No surprise that Testosterone therapy improves Testosterone levels in men with low T, but aromatase inhibition (AI) did as well.  In this study, only lean mass increased compared to Testosterone therapy and placebo.  Strength increased in both Testosterone and AI.

Nice review of the proposed complex interaction between hormones and prostate cancer.  The complex nature of the development of cancer will likely eliminate the complete elucidation of the mechanism of prostate cancer.  However, there are many pieces that would favor: increased aromatase activity appears to play a significant role int he development of prostate cancer, clearly intraprostatic hormones are different than serum making serum evaluation of sex hormones irrelevant--the move should be to salivary hormones, and the growing knowledge of DHT metabolites in the protection of prostate cancer--3 beta androstanediol.

Study finds no improvement in sexual desire and/or ED in older, obese men with Type II diabetes by Testosterone therapy over 40 weeks.   There is so much wrong with this study.  The authors, by design, assume that Testosterone is all there is.  No assessment of Testosterone metabolism and or its effects on inflammation was designed into this study.  These men are known to have increased inflammatory cytokine production and likely are aromatase dominant.  Given these men Testosterone may just be throwing fuel on the biochemical fire.

Men with type II diabetes have lower Testosterone levels when compared to none diabetics.  This study found an increased mortality with low T in those with type II Diabetes.  The main association was found with bioavailable Testosterone.  Total Testosterone is proving useless as a functional tool.  Additionally, Testosterone therapy reduced mortality in those with Diabetes.

Testosterone therapy in men with CHF found to increase exercise capacity, reduced the Q-T interval in men, improved muscle strength in men, and was found to be safe in meta-analysis.

new study finds that men >65 with low libido and Testosterone levels < 275 increase sexual function with Testosterone therapy.  Only libido was improved; no benefit to erectile function was noted--note that is likely due to depleted NO.  Given time that should improve with he increase in NO synthase and thus NO.  I have a fault with on elf the comments on this study: they point out that increased free Testosterone and estradiol levels were associated with improved sexual activity.  This lacks an understanding of the physiology.  In men with low T > 65, the majority are dealing with inflammation and excess weight; all of which increase aromatase activity and thus estradiol activity.  This does not indicate that an increase in estradiol activity is associated with improved libido in men.  How can elevated estrogen levels lead to low T and then increase levels are associated with improved libido?  This is merely a reflection of the body's dysfunctional physiology.  This observation of increased estradiol by no means shows cause and effect.  Scientists need to due a better job in vetting what they write!

Men with metabolic syndrome have lower Testosterone levels when compared to "healthy" individuals.  All men with MetS should have a full androgen analysis performed.  This meta-analysis of 20 studies found Testosterone therapy reduced fasting glucose, HOMA, triglycerides, waist circumference by Testosterone in men with MetS.  This study found that Testosterone therapy increased HDL as well.

Hormones and metabolic syndrome in men.  Low Testosterone, low free Testosterone and Increased SHBG associated with MetS in men.

IN men with low Testosterone, Testosterone therapy improved trabecular bone, but not cortical bone.  Growth hormone provided no additional benefit.  This study looked at men with panhypopituitarism.

Older men, 70-89, Testosterone in the middle range of normal and higher DHT was associated with the lowest death rates.  Estradiol was not found to be associated.  This study only looked at Total levels, free bioavailable levels were not assessed.  This study also highlights the basic thought, that more is not always better as it pertains to Testosterone.  It also highlights the importance of DHT.  Testosterone is a pro hormone.

Study finds that men with opiated induced low T have improvement in pain with Testosterone therapy.  Opiates are one of the many causes of low Testosterone (see my book Man Boob Nation).  Low T has been associated with increase inflammation in men.  Thus a normalization of Testosterone would provide anti-inflammatory effects.

study of Japanese men finds that low free Testosterone was a predictor of decrease in muscle mass.

Age seems to predict metabolism of testosterone in those receiving testosterone therapy.  Older men appear to have slower metabolism of testosterone.  This implies that one can likely dose "older" men at lower dosages.

low T is found in 20-70% of men with HIV.  What is interesting about this article is that Total Testosterone was found to be a poor assessment of biological active Testosterone.  Free Testosterone assessed in the am was shown to be a better functional assessment in these men.  Serum is a poor choice though.  The process of equilibrium dialysis to calculate free Testosterone is filled with variables that will effect reliability.  Increases SHBG was found associated.

This study appears to fly in the face of the recent studies on the dangers of Testosterone therapy in those with comorbidities.  This study was a retrospective cohort.  The study found that men in the highest risk for MI, had a reduced MI risk with Testosterone therapy.  Men in the lower risk quartiles had no such benefit.  Of note, the frequency of injections suggests inadequate dosing i.e. 4.4 in first year and 8.2 in follow up.  Most injection regimens will require at least monthly injections, though Testosterone pellets were used.  Of special note, no mention of level testing of Testosterone prior to study and/or during study and follow up.